France Javoy‐agid
#166,608
Most Influential Person Now
France Javoy‐agid's AcademicInfluence.com Rankings
France Javoy‐agidbiology Degrees
Biology
#13529
World Rank
#17079
Historical Rank
Neuroscience
#2354
World Rank
#2418
Historical Rank
Biochemistry
#2377
World Rank
#2527
Historical Rank
Download Badge
Biology
France Javoy‐agid's Degrees
- PhD Neuroscience Université Paris Cité
Why Is France Javoy‐agid Influential?
(Suggest an Edit or Addition)France Javoy‐agid's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease (1989) (1392)
- Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994) (1093)
- Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. (1997) (1038)
- Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. (1991) (976)
- Mitochondrial defect in Huntington's disease caudate nucleus (1996) (735)
- Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease (1983) (719)
- Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease (1994) (589)
- Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. (1987) (531)
- Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis (1991) (517)
- Glutathione peroxidase, glial cells and Parkinson's disease (1993) (437)
- A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics (1987) (334)
- Striatal dopamine deficiency in parkinson's disease: Role of aging (1989) (275)
- Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia (1982) (261)
- Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. (1996) (247)
- Dopaminergic and cholinergic lesions in progressive supranuclear palsy (1985) (232)
- [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. (1984) (227)
- Alterations of dopaminergic and noradrenergic innervations in motor cortex in parkinson's disease (1991) (220)
- Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease (1993) (216)
- Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? (1992) (216)
- Dopamine deficiency in the cerebral cortex in Parkinson disease (1982) (186)
- A subcortico-cortical cholinergic system is affected in Parkinson's disease (1983) (184)
- Somatostatin and dementia in Parkinson's disease (1983) (170)
- Parkinson's disease and dementia (1987) (163)
- Biochemistry of Parkinson's disease 28 years later: A critical review (1989) (161)
- Labeled wheat germ agglutinin (WGA) as a new, highly sensitive retrograde tracer in the rat brain hippocampal system (1978) (160)
- Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons (1994) (153)
- Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains (1983) (152)
- Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson's disease: An in situ hybridization study (1990) (150)
- Mitochondrial function and parental sex effect in Huntington's disease (1990) (144)
- Biochemical neuropathology of Parkinson's disease. (1984) (137)
- Are dopaminergic neurons selectively vulnerable to Parkinson's disease? (1993) (136)
- Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum (1995) (134)
- Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. (1994) (132)
- Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? (1990) (130)
- Abnormal Tau proteins in progressive supranuclear palsy (1991) (126)
- Progressive supranuclear palsy: anatomoclinical and biochemical considerations. (1987) (113)
- Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome (1991) (110)
- CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients (1982) (109)
- Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. (1985) (107)
- Peptides and Parkinson's disease (1985) (107)
- Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? (1993) (106)
- Distribution of Specific High‐Affinity Binding Sites for [3H]Imipramine in Human Brain (1981) (105)
- [3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain. (1993) (98)
- Enkephalin Dipeptidyl Carboxypeptidase (Enkephalinase) Activity: Selective Radioassay, Properties, and Regional Distribution in Human Brain (1982) (93)
- Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum (1996) (92)
- Tyrosine hydroxylase and methionine-enkephalin in the human mesencephalon Immunocytochemical localization and relationships (1983) (90)
- Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain (1995) (88)
- Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients (1986) (88)
- [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. (1988) (86)
- D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy (1988) (86)
- Biochemistry of the hypothalamus in Parkinson's disease (1984) (86)
- Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain (1983) (86)
- Dopamine, tremor, and Parkinson's disease (1992) (84)
- Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex (1989) (81)
- Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. (1996) (78)
- Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. (1985) (78)
- Superoxide dismutase and Parkinson's disease (1990) (78)
- Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. (1992) (77)
- c-fos protein-like immunoreactivity: Distribution in the human brain and over-expression in the hippocampus of patients with Alzheimer's disease (1992) (76)
- Biochemical substrates of mental disturbances in Parkinson's disease. (1984) (73)
- Laminar distribution of neocortical senile plaques in senile dementia of the alzheimer type (2004) (72)
- Characterization and autoradiographic distribution of neurotensin binding sites in the human brain (1985) (72)
- Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease (1993) (72)
- Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease (1985) (71)
- Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. (1984) (71)
- Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes (1996) (71)
- Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease (1981) (69)
- Microtopography of methionine-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and Parkinsonian brains (1982) (69)
- POST MORTEM STABILITY AND STORAGE IN THE COLD OF BRAIN ENZYMES (1979) (68)
- Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system (1994) (68)
- The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? (1990) (67)
- Micro topography of Tyrosine Hydroxylase, Glutamic Acid Decarboxylase, and Choline Acetyltransferase in the Substantia Nigra and Ventral Tegmental Area of Control and Parkinsonian Brains (1981) (66)
- Immunocytochemical Quantification of Tyrosine Hydroxylase at a Cellular Level in the Mesencephalon of Control Subjects and Patients with Parkinson's and Alzheimer's Disease (1993) (65)
- Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNA (1995) (64)
- Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine (1986) (64)
- Distribution of manganese-dependent superoxide dismutase in the human brain (1994) (63)
- Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy (1995) (59)
- Dementia in Parkinson's disease: Biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins (1993) (58)
- Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease (1993) (55)
- Characterization and visualization of neurotensin binding to receptor sites in human brain. (1984) (54)
- Autoradiographic localization of muscarinic cholinergic receptors at various segmental levels of the human spinal cord (1984) (53)
- Dissociation of neuropeptide Y and somatostatin in Parkinson's disease (1985) (53)
- Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson's disease. (1983) (52)
- Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy (1994) (49)
- Somatostatin messenger rna-containing neurons in Alzheimer's disease: An in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex (1994) (48)
- Regional Distribution of Neurotransmitter Synthesizing Enzymes in the Basal Ganglia of Human Brain (1980) (48)
- BRAIN HISTIDINE DECARBOXYLASE ACTIVITY IN PARKINSON'S DISEASE (1983) (47)
- Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. (1991) (47)
- Quantitative Autoradiography of Tyrosine Hydroxylase Immunoreactivity in the Rat Brain (1991) (47)
- Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain (1992) (46)
- Cortical cholinergic projections from the basal forebrain of the rat, with special reference to the prefrontal cortex innervation (1984) (46)
- Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease (1985) (43)
- Enkephalinergic Markers in Substantia Nigra and Caudate Nucleus from Parkinsonian Subjects (1984) (43)
- Glial fibrillary acidic protein and βA4 protein deposits in temporal lobe of aging brain and senile dementia of the Alzheimer type: Relation with the cognitive state and with quantitative studies of senile plaques and neurofibrillary tangles (1990) (42)
- Dynorphin levels in parkinsonian patients: Leu5-enkephalin production from either proenkephalin A or prodynorphin in human brain (1985) (42)
- Plasticity of nerve afferents to nigrostriatal neurons in parkinson's disease (1995) (41)
- Levels of MET-enkephalin, LEU-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment (1988) (40)
- [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation]. (1985) (39)
- Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects (1987) (38)
- Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon (1993) (36)
- Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys (1995) (36)
- Clinical and pathological features in hydrocarbon‐induced Parkinsonism (1996) (35)
- Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography (1994) (34)
- Glycine Receptors in the Human Substantia Nigra as Defined by [3H]Strychnine Binding (1982) (32)
- Pathophysiology of L-dopa-induced abnormal involuntary movements. (1985) (32)
- Pro-opiomelanocortin peptides in the human hypothalamus: Comparative study between normal subjects and parkinson patients (1985) (32)
- METHIONINE-ENKEPHALIN DEFICIENCY IN BRAINS OF PATIENTS WITH PARKINSON'S DISEASE (1981) (32)
- I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease (1997) (31)
- Localization of copper-zinc superoxide dismutase mRNA in human hippocampus by in situ hybridization (1989) (31)
- Lack of Change in Basal Ganglia Neuropeptide Content Following Subacute 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment of the Common Marmoset (1986) (31)
- Neurochemical Investigations into the Human Area Postrema (1986) (30)
- Parkinson's disease and Alzheimer's disease: neurodegenerative disorders due to brain antioxidant system deficiency? (1990) (30)
- Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. (1993) (29)
- Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects. (1982) (28)
- Microtopography of d1 dopaminergic binding sites in the human substantia nigra: An autoradiographic study (1990) (27)
- Dopamine and methionine-enkephalin in human brain (1982) (27)
- Neuropeptides and Parkinson's disease. (1986) (27)
- DA Uptake Sites, D1, and D2 Receptors, D2 and Preproenkephalin mRNAs and Fos Immunoreactivity in Rat Striatal Subregions after Partial Dopaminergic Degeneration (1996) (26)
- l‐Histidine Decarboxylase in the Human Brain: Properties and Localization (1980) (26)
- Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus (1985) (26)
- Brain muscarinic cholinergic receptors in Huntington's disease (1992) (24)
- Compartmental ordering of cholinergic innervation in the mediodorsal nucleus of the thalamus in human brain (1990) (24)
- GABAA receptor complex function in frontal cortex membranes from control and neurological patients. (1991) (24)
- Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. (1996) (24)
- Tyrosine hydroxylase gene expression in human ventral mesencephalon: Detection of tyrosine hydroxylase messenger RNA in neurites (1990) (23)
- Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum (1993) (23)
- Cholinergic and peptidergic systems in PSP. (1994) (22)
- Decrease of serotonin‐S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy (1988) (22)
- Parkinson's Disease and Dementia (1986) (21)
- Biochemical mapping of cholecystokinin-, substance P-, [met]enkephalin-, [leu]enkephalin- and dynorphin a (1–8)-like immunoreactivities in the human cerebral cortex (1988) (21)
- Histofluorescence analysis of several systems of catecholaminergic nerve fibres within the rat neostriatum revealed by either restricted lesions of the substantia nigra or γ-hydroxybutyrate (1982) (20)
- Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy (1988) (19)
- Comparison of [3H] phencyclidine ([3H] PCP) and [3H] N-[1-(2-thienyl) cyclohexyl] piperidine ([3H] TCP) binding properties to rat and human brain membranes. (1989) (18)
- Brain neuropeptides in progressive supranuclear palsy (1987) (17)
- Evidence for the Existence of a Dopaminergic Innervation of the Rat and Human Hippocampal Formation (1982) (17)
- Identification of new human myelin basic protein transcripts in the immune and central nervous systems (1994) (16)
- Pitfalls in membrane binding sites studies in post-mortem human brain. (1987) (16)
- Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. (1987) (15)
- [3H]spiperone binding in the nigrostriatal system in human brain. (1984) (15)
- monoclonal antibodies raised against Lewy bodies in brains from subjects with Parkinson's disease (1985) (15)
- Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects (1988) (15)
- Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. (1979) (14)
- Thyrotropin releasing hormone content is unchanged in brains of patients with Parkinson disease (1983) (14)
- Is dopaminergic cell death accompanied by concomitant nerve plasticity? (1996) (14)
- Galanin receptors in human hypothalamus: biochemical and structural analysis. (1994) (13)
- Preservation of Somatostatin Receptors Coupled to the Inhibition of Adenylate Cyclase in the Cortex and Hippocampus in Senile Dementia of the Alzheimer Type (1991) (13)
- Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease (1994) (13)
- Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease (1994) (13)
- In situ hybridization of GAD mRNA in monkey and human brain: quantification at both regional and cellular levels (1993) (13)
- Gangliosides and parkinsonism (1993) (12)
- Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy (1988) (11)
- Dopamine denervation, age of onset, and Parkinson's disease (1995) (11)
- Hippocampal and Parahippocampal Somatostatin 28 and Neuropeptide Y Containing Neurons in Alzheimer's Disease (Part 1 of 2) (1992) (10)
- Quantitative Autoradiographic Localization of Dopamine Receptors and Uptake Sites in the Rat and Human CNS (1985) (9)
- Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease (1993) (9)
- Dopaminergic Cell Death in Parkinson’s Disease (1992) (9)
- Measurement of nerve growth factor-like immunoreactivity in human brain using an anti-mouse-NGF enzyme immunoassay (1992) (9)
- Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from parkinsonian patients. (1988) (9)
- Somatostatin alterations and brain diseases. (1985) (6)
- WHAT CAUSES PARKINSON'S DISEASE? (1984) (6)
- Brain somatostatin concentrations do not decrease in progressive supranuclear palsy. (1987) (6)
- Ultrastructural relations between nigrostriatal dopaminergic neurons and cholinergic nerve endings in the human brain. (1993) (5)
- Cholecystokininin Octapeptide Immunoreactivity Distribution in Human Brain (1985) (5)
- Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease. (1985) (5)
- Adrenal transplant, dopaminergic neurons, and Parkinson' disease (1993) (4)
- Glycine receptors in the human brain: characterization of 3H-strychnine binding and status in pathological conditions. (1983) (4)
- Autoradiographic study of [125Iepidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem (1993) (4)
- Factors Associated to Dopaminergic Cell Death in Parkinson's Disease (1994) (3)
- Enkephalin dipeptidyl carboxypeptidase ("enkephalinase"): assay, properties, and distribution in human brain and exploration of the active site. (1982) (3)
- Simultaneous measurement of β-endorphin- and γ-lipotropin-like peptides in the human hypothalamus (1981) (3)
- STRIATAL GLUTAMATE DECARBOXYLASE VALUES, INDICATIVE OF HOSPITAL WHERE PATIENT DIED (1984) (3)
- Parkinson's Disease Brain Bank in Paris: an evolutive bank responding to the exigencies of new neurochemical methodologies. (1993) (2)
- Contents Vol. 3, 1992 (1992) (1)
- Sensitivity of cholinergic neurons to GABAergic and serotoninergic drugs in the rat striatum. (1979) (0)
- Preferential expression of superoxide dismutase gene in the neuromelanin-pigmented neurons of the substantia Nigra: Implications for parkinson's disease (1990) (0)
- Subject Index Vol 3, 1992 (1992) (0)
- Distribution of [3H]SCH 23390 Binding Sites in the Human Substantia Nigra (1991) (0)
- Neuronal-specific expression of copper-zinc superoxide dismutase gene in transgenic mice: Animal model of gene dosage effect in down's syndrome (1990) (0)
- Neuropeptides in the basal ganglia of patients with Parkinson's or Steele‐Richardson's disease (1989) (0)
- Opioid Peptides and their Relevance for CNS Mechanisms; Role of “Enkephalinase” (Enkephalin-Dipeptidylcarboxypeptidase) as Synaptic Neuropeptidase (1982) (0)
- REPLY FROM A. KASTNER, E. C. HIRSCH, F. JAVOY‐AGID, O. LEJEUNE, O. RASCOL, AND Y. AGID (1993) (0)
- Dopaminergic cell death in Parkinson’s disease: a role of iron? (1993) (0)
- Putative role of tumor necrosis factor in the loss of dopaminergic neurons in Parkinson's disease (1992) (0)
This paper list is powered by the following services:
